LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

LLY

930.6

-5.49%↓

JNJ

238.04

-1.99%↓

ABBV

219.84

-0.68%↓

NVS

154.48

+0.12%↑

AZN

191.24

-0.38%↓

Search

CareDx Inc

Gesloten

SectorGezondheidszorg

17.6 2.03

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

16.98

Max

17.72

Belangrijke statistieken

By Trading Economics

Inkomsten

-5.8M

-4.1M

Verkoop

8.3M

108M

K/W

Sectorgemiddelde

14.645

61.417

EPS

0.12

Winstmarge

-3.79

Werknemers

761

EBITDA

-5.7M

1.5M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+44.34% upside

Dividenden

By Dow Jones

Volgende Winsten

29 apr 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-88M

912M

Vorige openingsprijs

15.57

Vorige sluitingsprijs

17.6

Nieuwssentiment

By Acuity

81%

19%

330 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

CareDx Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 mrt 2026, 22:42 UTC

Winsten

Prudential PLC 2025 Adjusted Operating Profit Rises

17 mrt 2026, 21:40 UTC

Winsten

Alimentation Couche-Tard Records Higher Profit, Revenue in 3Q

17 mrt 2026, 23:56 UTC

Marktinformatie

BHP's Next CEO Likely to Build On Existing Strategic Direction -- Market Talk

17 mrt 2026, 23:46 UTC

Marktinformatie

Nikkei May Rise After Recent Selloffs -- Market Talk

17 mrt 2026, 23:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

17 mrt 2026, 23:42 UTC

Marktinformatie

RBA's Return to Policy Tightening Will Work -- Market Talk

17 mrt 2026, 23:38 UTC

Marktinformatie

Gold Edges Lower on Possible Position Adjustments Before FOMC Decision -- Market Talk

17 mrt 2026, 23:24 UTC

Marktinformatie

Global Energy Roundup: Market Talk

17 mrt 2026, 23:24 UTC

Marktinformatie

New Woodside CEO Seen as Low-Risk Appointment -- Market Talk

17 mrt 2026, 22:22 UTC

Marktinformatie

BHP Hands Reins to Growth-Focused Executive -- Market Talk

17 mrt 2026, 22:20 UTC

Winsten

Prudential PLC 2025 New Business Profit $2.78B Vs. $2.46B >2378.HK

17 mrt 2026, 22:20 UTC

Winsten

Prudential PLC 2025 Adj Operating Profit $3.31B Vs. $3.13B >2378.HK

17 mrt 2026, 22:07 UTC

Winsten

Nvidia Says It Is Restarting Production of AI Chips for Sale in China -- WSJ

17 mrt 2026, 22:05 UTC

Winsten

ZTO Express (Cayman): Frank Zhen Wei to Resign From Board

17 mrt 2026, 22:04 UTC

Winsten

ZTO Express (Cayman): Board Approves Repurchase of Up to $1.5B of Shares Over Next 24 Months >ZTO

17 mrt 2026, 22:03 UTC

Winsten

ZTO Express (Cayman) Raises Semiannual Dividend to 39c Vs. 30c >ZTO

17 mrt 2026, 22:01 UTC

Winsten

ZTO Express (Cayman) 4Q Adj EPS 47c >ZTO

17 mrt 2026, 22:01 UTC

Winsten

ZTO Express (Cayman) 4Q Rev $2.08B >ZTO

17 mrt 2026, 22:01 UTC

Winsten

ZTO Express (Cayman) 4Q EPS 47c >ZTO

17 mrt 2026, 21:26 UTC

Winsten

Oklo Stock Wavers After Earnings, but the Nuclear Start-Up Has Good News -- Barrons.com

17 mrt 2026, 21:09 UTC

Winsten

Couche-Tard: 12 Company-Operated Stores Acquired During 3Q

17 mrt 2026, 21:08 UTC

Winsten

Couche-Tard 3Q Consolidated Same-Store Merchandise Revenue Up 2% >ATD.T

17 mrt 2026, 21:08 UTC

Winsten

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mrt 2026, 21:07 UTC

Winsten

Couche-Tard 3Q EPS 82c >ATD.T

17 mrt 2026, 21:06 UTC

Winsten

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mrt 2026, 21:05 UTC

Winsten

Couche-Tard 3Q Adj EPS 81c >ATD.T

17 mrt 2026, 21:05 UTC

Winsten

Couche-Tard 3Q Rev $21.8B >ATD.T

17 mrt 2026, 21:05 UTC

Winsten

Couche-Tard 3Q EPS 82c >ATD.T

17 mrt 2026, 21:05 UTC

Winsten

Couche-Tard 3Q Net $757.2M >ATD.T

17 mrt 2026, 20:50 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Energy & Utilities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

CareDx Inc Prognose

Koersdoel

By TipRanks

44.34% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 25 USD  44.34%

Hoogste 28 USD

Laagste 21 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor CareDx Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

2

Buy

4

Hold

0

Sell

Technische score

By Trading Central

14.77 / 18.49Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

330 / 351 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat